Weekly shot could replace daily insulin for thalassemia kids with diabetes
NCT ID NCT07370922
First seen Feb 01, 2026 · Last updated Jun 23, 2026 · Updated 24 times
Summary
This study tested a once-weekly injection called dulaglutide (a GLP-1 drug) against daily insulin in 80 children aged 10-18 with transfusion-dependent thalassemia and diabetes. The goal was to see if the weekly shot could control blood sugar just as well or better than insulin over 6 months. If successful, it could offer a simpler treatment option for these kids.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSFUSION DEPENDENT BETA-THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Faculty of medicine, Ain Shams University
Cairo, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dulaglutide (a once-weekly injection)
What this could lead to
If it works, this could give children with thalassemia-related diabetes a simpler once-weekly injection instead of daily insulin shots.
What could go wrong
This is a small, early-phase trial with only 80 participants. The drug may not control blood sugar as well as insulin, and side effects like nausea or stomach issues are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.